ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/10/2026
Back to search
Official data from USPTO
E-THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
E-THERAPEUTICS
ST13
US500000097497975Class
5, 9, 40, 42
Filing
97497975
Registration
7567980
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
06/11/2026
Trademark type
Word
Nice classes
5, 9, 40, 42
Filing date
07/11/2022
Registration date
11/19/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/19/2024
Last transaction
06/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
84
Owner location
LONDON, GB
Examiner
WOOD, CAROLINE
Law office
M10
Current location
INTENT TO USE SECTION
Holders and representatives
Holders
TANGRAM THERAPEUTICS PLC
E-THERAPEUTICS PLC
Representatives
Anna King BANNER & WITCOFF, LTD.
Technical classification
Nice Classes
Class 5Class 9Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blockingsilencinginhibiting gene expressionfor use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; none of the aforementioned goods forrelated toT-cells or T-cell receptors
Class 9
Downloadable and recorded computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the fields of pharmaceuticalsmedicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticalsmedicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticalsmedicines and drug discovery; downloadable databases in the field of pharmaceuticalsmedicines and drug discovery; electronic databases recorded on computer mediafor use in the field of pharmaceuticalsmedicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the fields of pharmaceuticalsmedicines and drug discovery; none of the aforementioned goods forrelated toT-cells or T-cell receptors
Class 40
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid; none of the aforementioned services forrelated toT-cells or T-cell receptors
Class 42
Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientificpharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientificpharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blocking gene expressionnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionandpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticalsmedicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blockingsilencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; designdevelopmentcreation and maintenance of computer platforms and computer software; designdevelopmentcreation and maintenance of computational computer software platforms; designdevelopmentcreation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicinesdrug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsshort interfering RNA (siRNA) medicinesnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticalsmedicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating pharmaceutical and medical preparationsfor use in the field of pharmaceuticalsmedicines and drug discovery; Software as a Service (SaaS); Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsgenerating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticalsmedicines and drug discoveryfor modelling genetic sequences and gene-disease associationsfor identifying and ranking potential gene targetsfor generating RNAi-based medicines and pharmaceuticalsnucleic acid-based drugs (NABDs) for blockingsilencing or inhibiting gene expressionpharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of informationadvice and consultancy services relating to all of the aforesaid; none of the aforementioned services forrelated toT-cells or T-cell receptors
Publications
History of USPTO decisions and trademark events.
31 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/19/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
11/19/2024
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
10/15/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
10/15/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/15/2024
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
09/26/2024
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
09/12/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/16/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/04/2024
PUBO
PUBLISHED FOR OPPOSITION
02/20/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/31/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/31/2024
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
01/18/2024
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/12/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/07/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
01/05/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/05/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
01/05/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/30/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/30/2023
ALIE
ASSIGNED TO LIE
11/30/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/26/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/27/2023
GNRT
NON-FINAL ACTION E-MAILED
04/27/2023
CNRT
NON-FINAL ACTION WRITTEN
04/27/2023
DOCK
ASSIGNED TO EXAMINER
04/25/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
04/19/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/29/2022
NWAP
NEW APPLICATION ENTERED
07/14/2022
Continuous trademark protection
Get notified about every new filing that threatens E-THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.